TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05003986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sparsentan
Description: Population 1: 800 mg Sparsentan (oral suspension)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sparsentan
Description: Population 2: 400 mg Sparsentan (oral suspension)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sparsentan
Description: Population 3: 400 mg Sparsentan (tablets)
Study: NCT06002763

Intervention type: OTHER
Intervention: PROMIS-29 v2.1 (Patient-Reported Outcomes Measurement Information System)
Description: PROMIS-29 is a survey designed to screen for pain, impairments in mood, physical function, and activities of daily living.
Study: NCT04598009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Taken orally (PO) twice a day (BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Taken orally (PO) once a day (QD)
Study: NCT06002763

Intervention type: OTHER
Intervention: PROMIS-29 v2.1 (Patient-Reported Outcomes Measurement Information System)
Description: PROMIS-29 is a survey designed to screen for pain, impairments in mood, physical function, and activities of daily living.

Intervention type: OTHER
Intervention: WHOQoLBREF (World Health Organization Quality of Life Brief Version)
Description: The WHOQOL-BREF is a 26-item version of the 100-item WHOQOL-100 quality of life measure that addresses four quality of life domains: physical health, psychological health, social relationships and environment.

Intervention type: OTHER
Intervention: WHOQoLBREF (World Health Organization Quality of Life Brief Version)
Description: The WHOQOL-BREF is a 26-item version of the 100-item WHOQOL-100 quality of life measure that addresses four quality of life domains: physical health, psychological health, social relationships and environment.

Intervention type: OTHER
Intervention: EQ-5D-3L1 (not an acronym)
Description: The EQ-5D-3L1 is a generic measure of health status consisting of two parts. The first part assesses health in five dimensions: MOBILITY, SELFCARE, USUAL ACTIVITIES, PAIN / DISCOMFORT, ANXIETY/DEPRESSION. The second part of the questionnaire consists of a VAS on which the patient rates their perceived health from 0 (the worst imaginable health) to 100 (the best imaginable health).

Intervention type: OTHER
Intervention: EQ-5D-3L1 (not an acronym)
Description: The EQ-5D-3L1 is a generic measure of health status consisting of two parts. The first part assesses health in five dimensions: MOBILITY, SELFCARE, USUAL ACTIVITIES, PAIN / DISCOMFORT, ANXIETY/DEPRESSION. The second part of the questionnaire consists of a VAS on which the patient rates their perceived health from 0 (the worst imaginable health) to 100 (the best imaginable health).
Study: NCT06449339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: Patients in the NSBB arm will receive generic carvedilol. The starting dose of oral carvedilol is 6.25mg daily (to be taken once or twice per day) and can be adjusted at each scheduled visit (either by increasing the dosage or frequency of dose administration) according to patients' tolerance, as well as the blood pressure and pulse rate that the systolic blood pressure should be not lower than 90 mmHg and pulse rate not lower than 55 beats per minute. The dosage of carvedilol can also be titrated or discontinued at unscheduled visit according to patient's condition. In case carvedilol is discontinued, it can be resumed from the starting dose at next scheduled visit if there is no contraindication for carvedilol. The dose of carvedilol will be kept at 6.25-12.5mg per day unless there are additional non-hepatic indications such as arterial hypertension or cardiac disease warranting higher carvedilol dosage. The maximum allowed dose of carvedilol is 50mg daily as per drug instruction.
Study: NCT06721663

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: selected physical therapy intervention
Description: therapeutic balance training and functional therapeutic exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: selected physical therapy intervention
Description: therapeutic balance training and functional therapeutic exercises
Study: NCT06721949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taurine
Description: Taurine is a naturally occurring amino sulfonic acid commonly found in the body. It is marketed as a natural health product/supplement and plays an important role in the body.
Study: NCT05783063

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham iTBS
Description: Mag-TD
Study: NCT06222502

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Planning, Reminders, and Micro-Incentives
Description: Participants will schedule planned walks during weekly phone calls with study staff. Participants will receive reminders for planned walks and receive micro-incentives after completion.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: Participants in this group will receive health education tips during weekly phone calls with study staff.
Study: NCT05301894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBI-827104
Description: T-type calcium channel blocker.
Study: NCT05735717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25mg/m2 IV on days -8 to -6 or days -4 to -2. 40mg/m2 IV on days -5 to -2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25mg/m2 IV on days -8 to -6 or days -4 to -2. 40mg/m2 IV on days -5 to -2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25mg/m2 IV on days -8 to -6 or days -4 to -2. 40mg/m2 IV on days -5 to -2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan 82.1 mg\*hr/L IV on days -5 to -2 or days -8 to -5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan 82.1 mg\*hr/L IV on days -5 to -2 or days -8 to -5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan 50 mg/m2 IV on days -4 to -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 200 mg/m2 intravenous given once on day-1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 200 mg/m2 intravenous given once on day-1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 200 mg/m2 intravenous given once on day-1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: As seizures have occurred following high dose busulfan, all patients will be treated with Keppra beginning day -6 and continuing until day -1 per institutional guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: As seizures have occurred following high dose busulfan, all patients will be treated with Keppra beginning day -6 and continuing until day -1 per institutional guidelines.
Study: NCT04274426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will administered by intravenous route
Study: NCT06028711

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education program
Description: Patients in a study group will participate in daily education program using an original brochure containing information on the benefits of appropriately adapted physical activity, practical tips on airway clearance techniques or physical exercise, and risk factors for exacerbation of COPD.
Study: NCT04274426

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin will administered by intravenous route

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated liposomal doxorubicin (PLD)
Description: PLD will be administered by intravenous route

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine will be administered by intravenous route

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel will be administered by intravenous route

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirvetuximab Soravtansine
Description: Mirvetuximab Soravtansine will be administered by intravenous route
Study: NCT05072977

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TransPRK
Description: A Merocel sponge is soaked in a saline solution to expand before being gently applied to the corneal surface in three gestures similar to painting. This standardised procedure avoids inhomogeneous wetting of the cornea, which would result in uneven ablation. The laser ablation is then performed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol PRK
Description: A ring is placed in the centre of the cornea and filled with 20% alcohol. After 20 seconds of exposure, the alcohol is absorbed with a small sponge and the corneal epithelium is debrided with a polyvinyl alcohol expanding sponge (Merocel, Medtronic). The entire cornea is rinsed with balanced salt solution and the epithelium is peeled away from the corneal stroma. The corneal bed is then dried with a small sponge and laser ablation is performed.
Study: NCT04999592

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care without prophylaxis
Description: Administer antibiotics in response to infection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis
Description: Ceftriaxone 2 gm IV q12h for 3 days
Study: NCT06650202

Intervention type: DEVICE
Group type: OTHER
Intervention: The Tethered Pelvic Assist Device (TPAD)
Description: a light-weight cable-driven robotic stand trainer that (i) can provide assistance-as-needed by applying corrective forces on the trunk and pelvis in response to their movement outside a pre-programmed area, and (ii) can apply controlled forces on the trunk and pelvis to perturb them from their nominal configuration during standing.
Study: NCT06649877

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-6194
Description: single injected dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-6194
Description: single injected dose
Study: NCT06651528

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TBRI
Description: The adapted TBRI WRA (Prison Only Component) will consist of an individual introductory module (1 hour) and a series of group modules (a minimum of 4 sessions, approximately 1-2 hours in length, delivered over the course of 3 months, with the final number and frequency to be determined in R61) focused on the core components of TBRI. The original TBRI approach includes a focus on group skills training; similarly, it is anticipated that R61 phase adaptations will meet the need for tailored skills training reflected by anticipated differences in the target population of women - including how their early attachment and trauma histories influence their current self-image and behavior (which likely has a tremendous impact on their relational attachments as adults). Group sessions will provide opportunities to build skills for regulating emotions and building healthy connections.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAU + TBRI + Re-entry Recovery Support
Description: This condition includes the proposed adapted TBRI as well as on-going re-entry recovery support with the Safe Support Person (SPP). The SSP will be identified by the study participant as someone who will provide prosocial support during re-entry (e.g., support towards abstinence, establishing healthy recovery support relationships, rebuilding relationships with family and children) and in most cases will involve a close family member (mother, grandmother) or friend at the woman's identified home placement. This individual will be identified by the study participant as someone who is not involved in active substance use nor has a current legal system status (e.g., on probation).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: Women in the TAU condition will not receive TBRI intervention services, but will receive traditional in-prison SUD treatment over 6 months as usual in the four targeted prison sites. The programs are separate units with the prisons and emphasize participation by all program members in the overall goal of addressing substance use and criminal thinking. Although trauma and violence are addressed as part of the holistic group process approach in these programs, these topics are not addressed from an on-going systematic or relational perspective and are not specifically addressed as part of re-entry planning.
Study: NCT06389240

Intervention type: OTHER
Intervention: 6 weeks post-operatively early weight bearing
Description: Early mobilization 6 weeks post-operatively. Gait analyses is carried out on when full mobilization is allowed. Gait analysis is performed while using force-measuring insoles (loadsol, Novel).

Intervention type: OTHER
Intervention: 10 weeks post-operatively weight bearing (standard of care)
Description: Standard of care mobilization at 10 weeks post-operatively. Gait analyses is carried out on when full mobilization is allowed. Gait analysis is performed while using force-measuring insoles (loadsol, Novel).
Study: NCT05416125

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisdexamfetamine Dimesylate
Description: Vyvanse treatment

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Lifestyle therapy
Description: Lifestyle treatment
Study: NCT06447532

Intervention type: PROCEDURE
Intervention: Surgery (Mastectomy or quadrantectomy)
Description: Surgery (mastectomy or quadrantectomy); Neoadjuvant chemotherapy
Study: NCT06023953

Intervention type: DEVICE
Intervention: Nerivio device
Description: REN treatment with Nerivio device

Intervention type: DEVICE
Intervention: Nerivio device
Description: REN treatment with Nerivio device
Study: NCT04983095

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiotherapy
Description: 30 Gy in 3 fractions alternatively 40 Gy in 5 fractions delivered with stereotactic radiotherapy-principles

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: androgen deprivation therapy
Description: Medical castration and next-generation Hormonal Agent along with radiotherapy to the prostate in de novo oligometastatic prostate cancer

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: androgen deprivation therapy
Description: Medical castration and next-generation Hormonal Agent along with radiotherapy to the prostate in de novo oligometastatic prostate cancer

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: RT to the prostate for de novo patients

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: RT to the prostate for de novo patients
Study: NCT05494151

Intervention type: DIAGNOSTIC_TEST
Intervention: Investigation of the metabolic substrate
Description: A blood sample will be received from each patient to assess novel metabolomic biomarkers' levels at the time of acute myocardial infraction

Intervention type: DIAGNOSTIC_TEST
Intervention: Investigation of the metabolic substrate
Description: A blood sample will be received from each patient to assess novel metabolomic biomarkers' levels at the time of acute myocardial infraction
Study: NCT06146517

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clevr Sleeptime
Description: Participants will trial Clevr Blends Sleeptime during weeks 1-4.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clevr Matcha
Description: Participants will trial Clevr Matcha during weeks 5-8.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clevr Chai
Description: Participants will trial Clevr Chai during weeks 9-12.
Study: NCT06652269

Intervention type: OTHER
Intervention: Psychopharmacology intervention
Description: Psychotherapy with horses
Study: NCT06652191

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Direct catheterization with non-dilation
Description: Under the guidance of real-time ultrasound, the right internal jugular vein was punctured and a guide wire was inserted, place the catheter into the vessel directly along the guide wire without using an dilator to expand the skin

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheterization after expanding the skin with a dilator
Description: Under the guidance of real-time ultrasound, the right internal jugular vein was punctured and a guide wire was inserted, after the skin is expanded with a dilator, the catheter is inserted into the vessel along the guide wire
Study: NCT06651996

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: one session of face-to-face telerehabilitation tutorial (OST)
Description: The first group participated in a face-to-face tele-rehabilitation session in the hospital on the use of sensors and rehabilitation software before the home-rehabilitation session. Thereafter, the tele-rehabilitation program included muscle strengthening, flexibility stretching, and movement quality training every Tuesday, Thursday, and Saturday.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Three session of face-to-face telerehabilitation tutorials (TST)
Description: The second group participated in three face-to-face tele-rehabilitation sessions in the hospital on the use of sensors and rehabilitation software before the home-rehabilitation session. Thereafter, the tele-rehabilitation program included muscle strengthening, flexibility stretching, and movement quality training every Tuesday, Thursday, and Saturday.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Six session of face-to-face telerehabilitation tutorials (SST)
Description: The third group participated in six face-to-face tele-rehabilitation sessions in the hospital on the use of sensors and rehabilitation software before the home-rehabilitation session. Thereafter, the tele-rehabilitation program included muscle strengthening, flexibility stretching, and movement quality training every Tuesday, Thursday, and Saturday.
Study: NCT06651645

Intervention type: OTHER
Intervention: COVID-19 Surge
Description: Impact of COVID-19 pandemic on hospital care delivery

Intervention type: OTHER
Intervention: COVID-19 Surge
Description: Impact of COVID-19 pandemic on hospital care delivery
Study: NCT06028711

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation
Description: The patients will participate in a 14-day rehabilitation program (Monday to Saturday). Treatments and therapies will be continued for a maximum of two hours daily. The program will be applied individually to each patient and include active and assisted exercises, effective cough exercises, pursed-lips breathing, positive expiratory pressure exercises, exercises to strengthen the diaphragm and intercostal muscles and cardiopulmonary exercises.

Intervention type: OTHER
Group type: OTHER
Intervention: Pulmonary rehabilitation
Description: The patients will participate in a 14-day rehabilitation program (Monday to Saturday). Treatments and therapies will be continued for a maximum of two hours daily. The program will be applied individually to each patient and include active and assisted exercises, effective cough exercises, pursed-lips breathing, positive expiratory pressure exercises, exercises to strengthen the diaphragm and intercostal muscles and cardiopulmonary exercises.
Study: NCT05676034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMX0035
Description: AMX0035
Study: NCT03935451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban 2.5 milligram
Description: 2.5 milligram daily dosing of Apixaban beginning on the first day of hospital discharge for a total of 30 days
Study: NCT05418842

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Description: In addition to usual care, the prehabilitation group will exercise 3 times a week, starting immediately after diagnosis and throughout the pre-treatment period. Each exercise session will encompass 5-min warm-up and 45-min conditioning exercises. Aerobic training will be performed using low-volume high intensity interval training (HIIT). The HIIT duration is 16-20 minutes and it will be performed with 8-10 intervals of high intensity (1 minute) and 8-10 intervals of low intensity (1 minute). High intensity intervals will be set to an external load that represents 85-90% of estimated VO2Peak. In addition, patients will do resistance training at moderate intensity. Patients will complete 2 sets of 12 repetitions of 5 upper and lower body exercises.
Study: NCT06327139

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional 5 point closed face immobilisation mask.
Description: The conventional closed face mask is a standard of care immobilization device for head and neck cancer patients which covers and immobilizes the entire anterior portion of the patients head, neck and shoulders using a semi rigid thermoplastic material.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 5 point open face immobilization mask
Description: The 5 point open face mask is a type of immobilization device for head and neck cancer patients which does not cover the patients face or chest. The device uses a semi rigid thermoplastic material and covers from the superior aspect of the patients head to the level of their clavicle.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3 point open face immobilization mask
Description: The 3 point open face mask is a type of immobilization device for head and neck cancer patients which does not cover the patients face. The device uses a semi rigid thermoplastic material and covers from the superior aspect of the patients head to the below the patients chin. The three point mask does not cover the patients shoulders and does not extend inferiorly to the level of the clavicle.
Study: NCT05712083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCMA CAR-T cells
Description: Each subject receive BCMA CAR T-cells by intravenous infusion
Study: NCT03935451

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: placebo oral tablet that resembles the experimental drug. To be taken with the same frequency and duration
Study: NCT05480488

Intervention type: DRUG
Group type: OTHER
Intervention: Midazolam
Description: Subjects will receive a single oral dose of 2 mg midazolam (Treatment A, B, and C).

Intervention type: DRUG
Group type: OTHER
Intervention: Warfarin
Description: Subjects will receive a single oral dose of 25 mg warfarin (Treatment A and B).

Intervention type: DRUG
Group type: OTHER
Intervention: Daridorexant
Description: Subjects will receive an o.d. oral dose of 50 mg daridorexant from Day 1 to Day 7 of Treatment B and a single oral dose of 50 mg daridorexant on Day 1 of Treatment C.